Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Blood Proteins
  • Carcinoma, Non-Small-Cell Lung
  • Exanthema
  • Lung Neoplasms
  • Proteomics

abstract

  • Absence of rash after 21 days of cetuximab therapy and the serum proteomic classifier, but not ordinal rash severity, were associated with NSCLC outcomes. Although in a small study, these observations were consistent with results from larger retrospective analyses.

publication date

  • January 4, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3893521

Digital Object Identifier (DOI)

  • 10.1186/1471-2407-14-5

PubMed ID

  • 24386952

Additional Document Info

start page

  • 5

volume

  • 14

number

  • 1